Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF(V600E) or BRAF(V600K) mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.

Robert C, Kicinski M, Dutriaux C, Routier É, Govaerts AS, Bührer E, Neidhardt EM, Durando X, Baroudjian B, Saiag P, Gaudy-Marqueste C, Ascierto PA, Arance A, Russillo M, Perrot JL, Mortier L, Aubin F, Dalle S, Grange F, Muñoz-Couselo E, Mary-Prey S, Amini-Adle M, Mansard S, Lebbe C, Funck-Brentano E, Monestier S, Eggermont AMM, Oppong F, Wijnen L, Schilling B, MandalÁ M, Lorigan P, van Akkooi ACJ

Open source

DOI: 10.1016/s1470-2045(25)00133-0
Published: 2025 Jun
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00133-0,
  title = {Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF(V600E) or BRAF(V600K) mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.},
  author = {Robert C and Kicinski M and Dutriaux C and Routier É and Govaerts AS and Bührer E and Neidhardt EM and Durando X and Baroudjian B and Saiag P and Gaudy-Marqueste C and Ascierto PA and Arance A and Russillo M and Perrot JL and Mortier L and Aubin F and Dalle S and Grange F and Muñoz-Couselo E and Mary-Prey S and Amini-Adle M and Mansard S and Lebbe C and Funck-Brentano E and Monestier S and Eggermont AMM and Oppong F and Wijnen L and Schilling B and MandalÁ M and Lorigan P and van Akkooi ACJ},
  year = {2025},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00133-0},
  url = {https://doi.org/10.1016/s1470-2045(25)00133-0}
}

RIS

TY  - JOUR
TI  - Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF(V600E) or BRAF(V600K) mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.
AU  - Robert C
AU  - Kicinski M
AU  - Dutriaux C
AU  - Routier É
AU  - Govaerts AS
AU  - Bührer E
AU  - Neidhardt EM
AU  - Durando X
AU  - Baroudjian B
AU  - Saiag P
AU  - Gaudy-Marqueste C
AU  - Ascierto PA
AU  - Arance A
AU  - Russillo M
AU  - Perrot JL
AU  - Mortier L
AU  - Aubin F
AU  - Dalle S
AU  - Grange F
AU  - Muñoz-Couselo E
AU  - Mary-Prey S
AU  - Amini-Adle M
AU  - Mansard S
AU  - Lebbe C
AU  - Funck-Brentano E
AU  - Monestier S
AU  - Eggermont AMM
AU  - Oppong F
AU  - Wijnen L
AU  - Schilling B
AU  - MandalÁ M
AU  - Lorigan P
AU  - van Akkooi ACJ
PY  - 2025
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00133-0
UR  - https://doi.org/10.1016/s1470-2045(25)00133-0
ER  -

APA

C, R., M, K., C, D., É, R., AS, G., E, B., EM, N., X, D., B, B., P, S., C, G., PA, A., A, A., M, R., JL, P., L, M., F, A., S, D., F, G., E, M., S, M., M, A., S, M., C, L., E, F., S, M., AMM, E., F, O., L, W., B, S., M, M., P, L., & ACJ, V. A. (2025). Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF(V600E) or BRAF(V600K) mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00133-0

Source records

pubmed · retrieved 2026-09-26T01:28:11.628Z
europe-pmc · retrieved 2026-09-26T01:28:11.635Z